Dublin, Nov. 03, 2023 (GLOBE NEWSWIRE) The "Heart Failure in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. This report delves into the Heart Failure (HF) market across the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides a detailed forecast model through 2032. It's a comprehensive analysis of HF therapeutics, encompassing a wide range of factors that will s
Financial Year 2021/22 – Full Year Performance Chief Executive Officer’s Review Hemas Holdings PLC (HHL) accomplished a solid performance for the financial year 2021/2022 despite a challenging environment, to record a cumulative Group revenue of Rs. 78.8 billion, an increase of 22.2 per cent over the prior year. The overall cumulative operating profits of Rs.
The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed-dose and must be taken twice daily to improve glycemic control in patients
The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed-dose and must be taken twice daily to improve glycemic control in patients
Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed-dose combination (FDC) of its novel, patent-prote